Morpholine hydrazone scaffold: Synthesis, anticancer activity and docking studies

• Published in: Chinese Chemical Letters
• Main Author: Taha M.; Ali Shah S.A.; Afifi M.; Zulkeflee M.; Sultan S.; Wadood A.; Rahim F.; Ismail N.H.
• Format: Article
• Language: English
• Published: Elsevier B.V. 2017
• Online Access: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85006698949&doi=10.1016%2fj.cclet.2016.10.020&partnerID=40&md5=544d1e71d7a5c3349bec932e4de8b7b0

In this paper, synthesis and anticancer activities of morpholine hydrazones scaffold (1-17) thoroughly studied. Small series of morpholine hydrazones synthesized by treating 5-morpholinothiophene-2-carbaldehyde with different aryl hydrazides to form morpholine hydrazones scaffold (1-17). The in vitro anticancer potential of all these compounds was checked against human cancer cell lines like HepG2 (human hepatocellular liver carcinoma) and MCF-7 (human breast adenocarcinoma). Analogs 13 had similar substantial cytotoxic effects towards HepG2 with IC50 value 6.31 ± 1.03 μmol/L when compared with the standard Doxorubicin (IC50 value 6.00 ± 0.80 μmol/L); while compounds 5, 8 and 9 showed potent cytotoxicity against MCF-7 with IC50 value 7.08 ± 0.42 μmol/L, 1.26 ± 0.34 μmol/L and 11.22 ± 0.22 μmol/L respectively when compared with the standard Tamoxifen (IC50 = 11.00 ± 0.40 μmol/L). Molecular docking studies also performed to understand the binding interaction. © 2016 Muhammad Taha, Syed Adnan Ali Shah